Experimental Medication BMS-986165 for Crohn's Disease
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Bristol-Myers Squibb
Prior Safety Data
Trial Summary
What is the purpose of this trial?The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
Eligibility Criteria
This trial is for adults with moderate to severe Crohn's Disease who haven't responded well to standard treatments. They must have been diagnosed at least 3 months ago and agree to use contraception if needed. People with other types of colitis, previous BMS-986165 use, or those likely needing surgery/hospitalization for their condition can't participate.Treatment Details
The study is testing the safety and effectiveness of a new medication called BMS-986165 against a placebo in people with active Crohn's Disease. Participants will be randomly assigned to receive either the experimental drug or a placebo.
3Treatment groups
Experimental Treatment
Placebo Group
Group I: BMS-986165 Dose 2Experimental Treatment1 Intervention
Group II: BMS-986165 Dose 1Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a clinic near you
Research locations nearbySelect from list below to view details:
Huron Gastroenterology AssociatesYpsilanti, MI
University of Florida Health - JacksonvilleJacksonville, FL
Gastroenterology Research of San AntonioSan Antonio, TX
Local InstitutionMilwaukee, WI
More Trial Locations
Loading ...
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor